WO2013002490A1 - Biomarqueur pour le diagnostic du cancer du sein - Google Patents

Biomarqueur pour le diagnostic du cancer du sein Download PDF

Info

Publication number
WO2013002490A1
WO2013002490A1 PCT/KR2012/003882 KR2012003882W WO2013002490A1 WO 2013002490 A1 WO2013002490 A1 WO 2013002490A1 KR 2012003882 W KR2012003882 W KR 2012003882W WO 2013002490 A1 WO2013002490 A1 WO 2013002490A1
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
biomarker
mamdc2
gene
present
Prior art date
Application number
PCT/KR2012/003882
Other languages
English (en)
Korean (ko)
Inventor
맹필재
송영자
박영우
송규상
서광선
이진선
성경미
유석호
Original Assignee
충남대학교 산학협력단
(주)에이앤알쎄라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 충남대학교 산학협력단, (주)에이앤알쎄라퓨틱스 filed Critical 충남대학교 산학협력단
Publication of WO2013002490A1 publication Critical patent/WO2013002490A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to a biomarker for diagnosing breast cancer, and in particular, provides a biomarker for diagnosing breast cancer comprising a specific DNA fragment or full-length DNA of MAMDC2.
  • Breast cancer is the second most common cancer in the world, after lung cancer, and mortality is the fifth most dangerous cancer.
  • early detection is more important than other cancers because cancer is difficult to cure once cancer cells invade surrounding tissues or begin to metastasize to lymph nodes.
  • breast X-ray angiography and ultrasonography are used as preventive screening methods, and this method is most widely used to diagnose early breast cancer.
  • breast x-ray angiography is a dense breast that is commonly found in Korean women because of the high fiber, the diagnosis rate is low, especially the younger women, even if a lot of mammary gland development rate is low.
  • the use of X-rays does not rule out the possibility of developing breast cancer in the course of diagnosis.
  • ultrasonography is used, but it is also difficult to distinguish between malignant and non-cancer tumors.
  • diagnosis rate is increased by additionally using fine needle aspiration cytology and magnetic resonance imaging.
  • fine needle aspiration cytology and magnetic resonance imaging Even if these methods are used to distinguish between normal and abnormal tissues in a morphological form, it is not easy to distinguish between cancerous and non-cancer tumors.
  • breast cancer has been developed to diagnose breast cancer in a relatively molecular genetic way compared to other cancers. The biopsy will reveal the lesion by cutting the tissue and then undergo a primary surgery for removal.
  • HER2 / neu also known as Human Epidermal Growth Factor Receptor 2, ErbB-2 or ERBB2
  • ERBB2 Human Epidermal Growth Factor Receptor 2
  • HER2 / neu also known as Human Epidermal Growth Factor Receptor 2, ErbB-2 or ERBB2
  • In situ hybridization is used. If the cancer tissue found has an estrogen receptor, it is treated with an estrogen analogue such as Tamoxifen, and if the HER2 / neu gene is overexpressed, Herceptin commercialized with the HER2 / neu monoclonal antibody trastuzumab. Herceptin will be used to treat breast cancer.
  • HER2 / neu gene the breast cancer specific diagnostic marker most useful for the diagnosis and treatment of breast cancer, is found in 20-35% of invasive breast cancers. therefore.
  • Oncotype DX is a method for screening 16 breast cancer genes and 5 control genes by real-time quantitative PCR
  • MammaPrint is a method for microarraying 70 genes.
  • the present inventors found that the expression level of the MAMDC2 gene included in tissues, in particular the expression level of a specific region of the gene transcript, was significantly associated with breast cancer using NanoString's nCounter Analysis System using clinical tissues.
  • a DNA fragment or full length DNA of the breast cancer gene is used as a biomarker for diagnosing breast cancer.
  • breast cancer When the expression level of the DNA fragment of MAMDC2 or the full-length DNA, which is a gene constituting the biomarker for diagnosing breast cancer of the present invention, from the tissue of the sample is measured and compared with the expression level in normal tissues, breast cancer can be effectively diagnosed. Breast cancer can be treated early.
  • 1 is a view showing the results of confirming the breast cancer diagnostic performance for MAMDC2.
  • the present invention relates to a biomarker for diagnosing breast cancer using a specific DNA fragment or full-length DNA of a gene that is expressed more specifically than normal tissue in breast cancer tissues, the DNA fragment or full-length DNA of the MAMDC2 gene comprising the polynucleotide of SEQ ID NO: 1 I use it. Since the MAMDC2 gene is characterized in that it is expressed more specifically in breast cancer tissue than normal tissue, the full-length DNA of the gene may be used as a biomarker for diagnosing breast cancer, and in particular, the MAMDC2 gene including the polynucleotide of SEQ ID NO: 1 in the sample tissue. DNA fragments can also be used as biomarkers for breast cancer diagnosis because the amount of DNA fragments can indirectly measure the quantitative expression level of the MAMDC2 gene.
  • the method for diagnosing breast cancer using the biomarker for diagnosing breast cancer of the present invention is not particularly limited as long as it is a method used in the art.
  • NanoString's nCounter Analysis system is an analytical device capable of digital mRNA profiling. It has the advantage of not needing cDNA synthesis process or amplification process of target to be measured. Therefore, total RNA, cell lysates, blood The advantage is that it can be analyzed if only a simpler sample such as lysates or FFPE sample is prepared.
  • a) total RNA from a sample's breast tissue is directly directed to an nCounter probe comprising a reporter probe and a capture probe.
  • information on the MAMDC2 gene and the probe used as a biomarker for diagnosing breast cancer is shown in Table 1.
  • the clinical tissue of breast cancer is Chungnam National University Hospital Korea National Resource Bank (IRB) through IRB approval of matched normal and cancer tissues in the vicinity of cancer tissues of the same patient as cancer tissues of breast cancer patients. of Korea), the tissues of 100 patients were used, and the breast cancer clinical tissues were kept frozen at -70 ° C. Extraction of total RNA from breast cancer clinical tissues was recommended using TRI REAGENT (MRC). Total RNA was extracted and dissolved in DEPC (RNase inhibitor) -treated water.
  • DEPC RNase inhibitor
  • MAMDC2 showed a decrease in expression in breast cancer tissues, and thus, MAMDC2 could be verified as a biomarker for diagnosing breast cancer.
  • the breast cancer diagnostic biomarker (MAMDC2) of the present invention has a high specificity (95.7) and sensitivity ( 93.4).
  • the present invention can effectively diagnose breast cancer, through which it is possible to treat breast cancer early.
  • SEQ. ID. NO. 1 polynucleotide fragment of MAMDC2 gene: AGGGAGGTTATGTTGCCCTGGATGATATTTCATTCTCTCCTGTTCACTGCCAGAATCAGACAGAACTTCTGTTCAGTGCCGTGGAAGCCAGCTGCAATTT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un biomarqueur pour le diagnostic du cancer du sein, et plus particulièrement concerne un biomarqueur pour le diagnostic du cancer du sein, comprenant un fragment d'ADN spécifique ou un ADN de longueur totale de MAMDC2. Il est possible de diagnostiquer efficacement le cancer du sein par la mesure du niveau d'expression d'un fragment d'ADN ou d'un ADN de longueur totale de MAMDC2 qui est le gène constituant le biomarqueur de diagnostic pour le cancer du sein de la présente invention, à partir du tissu d'un échantillon, et la comparaison du résultat mesuré avec le niveau d'expression d'un tissu normal, et il est possible de traiter le cancer du sein à un stade précoce par ce procédé.
PCT/KR2012/003882 2011-06-30 2012-05-17 Biomarqueur pour le diagnostic du cancer du sein WO2013002490A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0065194 2011-06-30
KR1020110065194A KR101441013B1 (ko) 2011-06-30 2011-06-30 유방암 진단용 바이오마커

Publications (1)

Publication Number Publication Date
WO2013002490A1 true WO2013002490A1 (fr) 2013-01-03

Family

ID=47424347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003882 WO2013002490A1 (fr) 2011-06-30 2012-05-17 Biomarqueur pour le diagnostic du cancer du sein

Country Status (2)

Country Link
KR (1) KR101441013B1 (fr)
WO (1) WO2013002490A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105624279A (zh) * 2015-01-22 2016-06-01 香港中文大学深圳研究院 胃癌标记物、其表达和甲基化检测方法、试剂盒及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102424255B1 (ko) * 2020-10-30 2022-07-22 경북대학교 산학협력단 인간 유방암 및 동물 유선암의 진단 및 악성도 평가를 위한 바이오마커로서 smp30의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194229A1 (en) * 2005-01-25 2006-08-31 Sky Genetics, Inc. Cancer markers and detection methods
WO2010127399A1 (fr) * 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Profils d'expression génétique et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120053080A1 (en) * 2009-03-09 2012-03-01 Juan Cui Protein markers identification for gastric cancer diagnosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194229A1 (en) * 2005-01-25 2006-08-31 Sky Genetics, Inc. Cancer markers and detection methods
WO2010127399A1 (fr) * 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Profils d'expression génétique et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 30 December 2010 (2010-12-30), accession no. M_153267.4 *
MARELLA ET AL.: "Cytogenetic and cDNA microarray expression analysis of MCF 1 human breast cancer progression cell line", CANCER RESEARCH, vol. 69, 7 July 2009 (2009-07-07), pages 5946 - 5953 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105624279A (zh) * 2015-01-22 2016-06-01 香港中文大学深圳研究院 胃癌标记物、其表达和甲基化检测方法、试剂盒及应用

Also Published As

Publication number Publication date
KR101441013B1 (ko) 2014-09-18
KR20130003708A (ko) 2013-01-09

Similar Documents

Publication Publication Date Title
CN102549169B (zh) 子宫内膜癌的标记物
EP1670946B1 (fr) Prevision du resultat d'un traitement contre le cancer du sein
RU2550925C2 (ru) Диагностика и лечение рака молочной железы
EP2210942B1 (fr) Gène associé au cancer du foie, et procédé de détermination du risque d'être atteint de cancer du foie
Lyng et al. Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography
EP2333119A1 (fr) Prévision du résultat d'un traitement contre le cancer du sein
EP3368684B1 (fr) Biomarqueur pour le cancer du sein
WO2013002490A1 (fr) Biomarqueur pour le diagnostic du cancer du sein
JP7453284B2 (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
CN110331207A (zh) 肺腺癌生物标志物及相关应用
EP2649225A2 (fr) Biomarqueurs pour la prédiction du cancer du sein
WO2010126338A2 (fr) Biomarqueur pour le diagnostic du cancer du sein et diagnostic du cancer du sein
De Palma et al. Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer
CN108929909A (zh) 一种甲状腺微小乳头状癌的转移性筛查的筛查试剂盒
Zangouri et al. Comparison of clinicopathologic characteristics and survival outcomes of various subtypes of breast cancer
KR102643326B1 (ko) 양성 종양 또는 결절로부터 암을 구분하기 위한 바이오마커
AU2002343900A1 (en) Diagnostic method for cancer characterized in the detection of the deletion of G-CSF exon 3
WO2003027288A1 (fr) Procede de diagnostic de cancer cacracterise par la detection de la deletion du 3eme exon de g-csf
Yang et al. Detection of aberrantly methylated tumor suppressor genes in breast cancer patients as a potential diagnostic biomarker
US20160194719A1 (en) A biomarker of breast cancer
KR101413690B1 (ko) 암 진단을 위한 메틸화 바이오 마커 ｔｅｓｃ 및 이의 용도
Sanna La proteomica plasmatica differenzia le pazienti con carcinoma mammario precoce dai controlli sani: un'analisi esplorativa dello studio RENOVATE.
US20150329914A1 (en) Predictive biomarkers for pre-malignant breast lesions
Panousis et al. Clinical characteristics and management of a Greek female patient cohort with breast ductal carcinoma in situ
CA3183417A1 (fr) Utilisation de pd-1 en tant que marqueur predictif pour une therapie contre le cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12805325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12805325

Country of ref document: EP

Kind code of ref document: A1